NCT06031194Completed
Pharmacogenomics Effects on High-Dose Methotrexate Clearance in Patients With Diffuse Large B-Cell Lymphoma
Source: ClinicalTrials.gov · Last updated 6 Jan 2026
Brief summary (registry, in English)
This study evaluates pharmacogenomic effects on high-dose methotrexate clearance in patients with diffuse large B-cell lymphoma.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 20 (actual)
- First submitted
- 31 Aug 2023
- Start date
- 10 May 2023
- Primary completion date
- 5 Nov 2025
- Lead sponsor
- Ohio State University Comprehensive Cancer Center
- Diseases
- Diffuse large B-cell lymphoma
- NCT number
- NCT06031194
What you commit to
- Study type: Observational
- Participants enrolled: 20
- From 10 May 2023 to the primary completion date, 5 Nov 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Lab values
- \* Patients with a "currently active" second malignancy that, in the opinion of the principal investigator, will interfere with patient participation, or confound data interpretation
- Pregnancy (positive serum or urine pregnancy test), lactating or breast feeding
- Prisoners or incarcerated patients
- Total bilirubin \> 5 mg/dL
Who the study is looking for
- \* Adult (age ≥ 18 years at diagnosis)
- Diagnosis of DLBCL or PCNSL
- Planned to undergo treatment with HDMTX (≥ 3 g/m\^2) at the James Cancer Hospital.
- Note: patients with CKD are eligible to participate regardless of eGFR provided the treating physician is planning a dose of HDMTX of at least 3 g/ m\^2.
- Ability to provide informed consent.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Ohio State University Comprehensive Cancer Center Coordinator of this site? Confirm its status | Columbus | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.